Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits major histocompatibility complex class II expression by disrupting enhanceosome assembly through binding with the regulatory factor X complex

Journal of Virology

Volumn 89, Issue 10, 2015, Pages 5536-5556

  Thakker, Suhani ^a   Purushothaman, Pravinkumar ^a   Gupta, Namrata ^a   Challa, Shanthan ^a   Cai, Qiliang ^b   Verma, Subhash C ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CLASS II TRANSACTIVATOR PROTEIN; ENHANCEOSOME; HLA DR ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REGULATORY FACTOR X COMPLEX; REGULATORY FACTOR X COMPLEX ANKYRIN CONTAINING PROTEIN; REGULATORY FACTOR X COMPLEX ASSOCIATED PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; HLA ANTIGEN CLASS 2; LATENCY-ASSOCIATED NUCLEAR ANTIGEN; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; PROTEIN BINDING; REGULATORY FACTOR X TRANSCRIPTION FACTORS; RFXAP PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VIRUS ANTIGEN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CARBOXY TERMINAL SEQUENCE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN HERPESVIRUS 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 GENE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CHEMISTRY; DOWN REGULATION; GENE; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

HUMAN HERPESVIRUS 8;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; GENES, MHC CLASS II; HEK293 CELLS; HERPESVIRUS 8, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ALPHA-CHAINS; HOST-PATHOGEN INTERACTIONS; HUMANS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 84928578545     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03713-14     Document Type: Article

References (78)

1. Cai Q, Verma SC, Lu J, Robertson ES. 2010. Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res 78: 87-142. http://dx.doi.org/10.1016/B978-0-12-385032-4.00003-3.
2. Cesarman E. 2014. Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol 9:349-372. http://dx.doi.org/10.1146/annurev-pathol-012513-104656.
3. Toth Z, Brulois K, Jung JU. 2013. The chromatin landscape of Kaposi's sarcoma-associated herpesvirus. Viruses 5:1346-1373. http://dx.doi.org/10.3390/v5051346.
4. Verma SC, Robertson ES. 2003. Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol Lett 222:155-163. http://dx.doi.org/10.1016/S0378-1097(03)00261-1.
5. Coscoy L. 2007. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol 7:391-401. http://dx.doi.org/10.1038/nri2076.
6. Lee HR, Brulois K, Wong L, Jung JU. 2012. Modulation of immune system by Kaposi's sarcoma-associated herpesvirus: lessons from viral evasion strategies. Front Microbiol 3:44. http://dx.doi.org/10.3389/fmicb.2012.00044.
7. Alibek K, Baiken Y, Kakpenova A, Mussabekova A, Zhussupbekova S, Akan M, Sultankulov B. 2014. Implication of human herpesviruses in oncogenesis through immune evasion and suppression. Infect Agents Cancer 9:3. http://dx.doi.org/10.1186/1750-9378-9-3.
8. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande JP, Weiss RA, Alitalo K, Boshoff C. 1999. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96:4546-4551. http://dx.doi.org/10.1073/pnas.96.8.4546.
9. Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS, Chang Y. 2000. Differential viral protein expression in Kaposi's sarcomaassociated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 156: 743-749. http://dx.doi.org/10.1016/S0002-9440(10)64940-1.
10. Kellam P, Bourboulia D, Dupin N, Shotton C, Fisher C, Talbot S, Boshoff C, Weiss RA. 1999. Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8. J Virol 73:5149-5155.
11. Mesri EA, Cesarman E, Boshoff C. 2010. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 10:707-719. http://dx.doi.org/10.1038/nrc2888.
12. Verma SC, Lan K, Robertson E. 2007. Structure and function of latencyassociated nuclear antigen. Curr Top Microbiol Immunol 312:101-136. http://dx.doi.org/10.1007/978-3-540-34344-8_4.
13. Li X, Liang D, Lin X, Robertson ES, Lan K. 2011. Kaposi's sarcomaassociated herpesvirus-encoded latency-associated nuclear antigen reduces interleukin-8 expression in endothelial cells and impairs neutrophil chemotaxis by degrading nuclear p65. J Virol 85:8606-8615. http://dx.doi.org/10.1128/JVI.00733-11.
14. Cloutier N, Flamand L. 2010. Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter. J Biol Chem 285:7208-7221. http://dx.doi.org/10.1074/jbc.M109.018838.
15. Zaldumbide A, Ossevoort M, Wiertz EJ, Hoeben RC. 2007. In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpes virus. Mol Immunol 44:1352-1360. http://dx.doi.org/10.1016/j.molimm.2006.05.012.
16. Kwun HJ, da Silva SR, Qin H, Ferris RL, Tan R, Chang Y, Moore PS. 2011. The central repeat domain 1 of Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) prevents cis MHC class I peptide presentation. Virology 412:357-365. http://dx.doi.org/10.1016/j.virol.2011.01.026.
17. Cai Q, Banerjee S, Cervini A, Lu J, Hislop AD, Dzeng R, Robertson ES. 2013. IRF-4-mediated CIITA transcription is blocked by KSHV encoded LANA to inhibitMHCII presentation. PLoS Pathog 9:e1003751. http://dx.doi.org/10.1371/journal.ppat.1003751.
18. Sabbah S, Jagne YJ, Zuo J, de Silva T, Ahasan MM, Brander C, Rowland-Jones S, Flanagan KL, Hislop AD. 2012. T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. Blood 119:2083-2092. http://dx.doi.org/10.1182/blood-2011-07-366476.
19. Zuo J, Rowe M. 2012. Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway. Viruses 4:1335-1353. http://dx.doi.org/10.3390/v4081335.
20. Cresswell P. 1994. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 12:259-293. http://dx.doi.org/10.1146/annurev.iy.12.040194.001355.
21. Ting JP, Zhu XS. 1999. Class II MHC genes: a model gene regulatory system with great biologic consequences. Microbes Infect 1:855-861. http://dx.doi.org/10.1016/S1286-4579(99)00233-6.
22. Hegde NR, Chevalier MS, Johnson DC. 2003. Viral inhibition of MHC class II antigen presentation. Trends Immunol 24:278-285. http://dx.doi.org/10.1016/S1471-4906(03)00099-1.
23. Schmidt K, Wies E, Neipel F. 2011. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression. J Virol 85:4530-4537. http://dx.doi.org/10.1128/JVI.02123-10.
24. Butler LM, Jeffery HC, Wheat RL, Long HM, Rae PC, Nash GB, Blackbourn DJ. 2012. Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3. J Virol 86:7158-7166. http://dx.doi.org/10.1128/JVI.06908-11.
25. Zuo J, Hislop AD, Leung CS, Sabbah S, Rowe M. 2013. Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and-independent mechanisms: implications for oncogenesis. J Virol 87:5340-5350. http://dx.doi.org/10.1128/JVI.00250-13.
26. Siegrist CA, Martinez-Soria E, Kern I, Mach B. 1995. A novel antigenprocessing-defective phenotype in major histocompatibility complex class II-positive CIITA transfectants is corrected by interferon-gamma. J Exp Med 182:1793-1799. http://dx.doi.org/10.1084/jem.182.6.1793.
27. van den Elsen PJ, van der Stoep N, Vietor HE, Wilson L, van Zutphen M, Gobin SJ. 2000. Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-gamma inducible promoter (PIV) of CIITA. Hum Immunol 61:850-862. http://dx.doi.org/10.1016/S0198-8859(00)00159-2.
28. Boss JM. 1997. Regulation of transcription ofMHCclass II genes. Current Opin Immunol 9:107-113. http://dx.doi.org/10.1016/S0952-7915(97)80166-5.
29. Krawczyk M, Reith W. 2006. Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. Tissue Antigens 67:183-197. http://dx.doi.org/10.1111/j.1399-0039.2006.00557.x.
30. Reith W, Mach B. 2001. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19:331-373. http://dx.doi.org/10.1146/annurev.immunol.19.1.331.
31. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman LJ, Peterlin BM. 2002. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) onDNArequires RFX5 dimers. Mol Cell Biol 22:5616-5625. http://dx.doi.org/10.1128/MCB.22.15.5616-5625.2002.
32. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, Reith W. 1997. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 16:1045-1055. http://dx.doi.org/10.1093/emboj/16.5.1045.
33. Hasegawa SL, Boss JM. 1991. Two B cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters. Nucleic Acids Res 19:6269-6276. http://dx.doi.org/10.1093/nar/19.22.6269.
34. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, Sanchez JC, Hochstrasser DF, Mach B, Reith W. 1998. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 20:273-277. http://dx.doi.org/10.1038/3081.
35. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM. 1999. CREB regulatesMHCclass II expression in a CIITA-dependent manner. Immunity 10:143-151. http://dx.doi.org/10.1016/S1074-7613(00)80015-1.
36. Moreno CS, Emery P, West JE, Durand B, Reith W, Mach B, Boss JM. 1995. Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J Immunol 155:4313-4321.
37. Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM. 1999. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 10:153-162. http://dx.doi.org/10.1016/S1074-7613(00)80016-3.
38. Reith W, Siegrist CA, Durand B, Barras E, Mach B. 1994. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y. Proc Natl Acad Sci U S A 91:554-558.
39. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, Reith W. 1995. A novel DNA-binding regulatory factor is mutated in primary MHCclass II deficiency (bare lymphocyte syndrome). Genes Dev 9:1021-1032. http://dx.doi.org/10.1101/gad.9.9.1021.
40. Ting JP, Trowsdale J. 2002. Genetic control of MHC class II expression. Cell 109(Suppl):S21-S33. http://dx.doi.org/10.1016/S0092-8674(02)00696-7.
41. Laird KM, Briggs LL, Boss JM, Summers MF, Garvie CW. 2010. Solution structure of the heterotrimeric complex between the interaction domains of RFX5 and RFXAP from the RFX gene regulatory complex. J Mol Biol 403:40-51. http://dx.doi.org/10.1016/j.jmb.2010.08.025.
42. Emery P, Durand B, Mach B, Reith W. 1996. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Res 24:803-807. http://dx.doi.org/10.1093/nar/24.5.803.
43. Hake SB, Masternak K, Kammerbauer C, Janzen C, Reith W, Steimle V. 2000. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation. Mol Cell Biol 20:7716-7725. http://dx.doi.org/10.1128/MCB.20.20.7716-7725.2000.
44. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 14:1156-1166. http://dx.doi.org/10.1101/gad.14.9.1156.
45. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W. 2004. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34:1513-1525. http://dx.doi.org/10.1002/eji.200424964.
46. Devaiah BN, Singer DS. 2013. CIITA and its dual roles in MHC gene transcription. Front Immunol 4:476. http://dx.doi.org/10.3389/fimmu.2013.00476.
47. Harton JA, Ting JP. 2000. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 20:6185-6194. http://dx.doi.org/10.1128/MCB.20.17.6185-6194.2000.
48. Verma SC, Cai Q, Kreider E, Lu J, Robertson ES. 2013. Comprehensive analysis of LANA interacting proteins essential for viral genome tethering and persistence. PLoS One 8:e74662. http://dx.doi.org/10.1371/journal.pone.0074662.
49. Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. 2006. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2:e116. http://dx.doi.org/10.1371/journal.ppat.0020116.
50. Kaul R, Verma SC, Robertson ES. 2007. Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology 364:317-329. http://dx.doi.org/10.1016/j.virol.2007.03.010.
51. Purushothaman P, McDowell ME, McGuinness J, Salas R, Rumjahn SM, Verma SC. 2012. Kaposi's sarcoma-associated herpesvirus-encoded LANA recruits topoisomerase IIbeta for latent DNA replication of the terminal repeats. J Virol 86:9983-9994. http://dx.doi.org/10.1128/JVI.00839-12.
52. Izumi KM. 2001. The yeast two-hybrid assay to identify interacting proteins. Methods Mol Biol 174:249-258. http://dx.doi.org/10.1385/1-59259-227-9:249.
53. Gao J, Cai Q, Lu J, Jha HC, Robertson ES. 2011. Upregulation of cellular Bcl-2 by the KSHV encoded RTA promotes virion production. PLoS One 6:e23892. http://dx.doi.org/10.1371/journal.pone.0023892.
54. Krithivas A, Young DB, Liao G, Greene D, Hayward SD. 2000. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol 74:9637-9645. http://dx.doi.org/10.1128/JVI.74.20.9637-9645.2000.
55. Hasegawa SL, Sloan JH, Reith W, Mach B, Boss JM. 1991. Regulatory factor-X binding to mutant HLA-DRA promoter sequences. Nucleic Acids Res 19:1243-1249. http://dx.doi.org/10.1093/nar/19.6.1243.
56. Peretti M, Villard J, Barras E, Zufferey M, Reith W. 2001. Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. Mol Cell Biol 21:5699-5709. http://dx.doi.org/10.1128/MCB.21.17.5699-5709.2001.
57. Nekrep N, Jabrane-Ferrat N, Peterlin BM. 2000. Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex. Mol Cell Biol 20:4455-4461. http://dx.doi.org/10.1128/MCB.20.12.4455-4461.2000.
58. Caretti G, Cocchiarella F, Sidoli C, Villard J, Peretti M, Reith W, Mantovani R. 2000. Dissection of functional NF-Y-RFX cooperative interactions on the MHC class II Ea promoter. J Mol Biol 302:539-552. http://dx.doi.org/10.1006/jmbi.2000.4028.
59. DeSandro AM, Nagarajan UM, Boss JM. 2000. Associations and interactions between bare lymphocyte syndrome factors. Mol Cell Biol 20: 6587-6599. http://dx.doi.org/10.1128/MCB.20.17.6587-6599.2000.
60. Garvie CW, Stagno JR, Reid S, Singh A, Harrington E, Boss JM. 2007. Characterization of the RFX complex and the RFX5(L66A) mutant: implications for the regulation of MHC class II gene expression. Biochemistry 46:1597-1611. http://dx.doi.org/10.1021/bi6023868.
61. Seguin-Estevez Q, De Palma R, Krawczyk M, Leimgruber E, Villard J, Picard C, Tagliamacco A, Abbate G, Gorski J, Nocera A, Reith W. 2009. The transcription factor RFX protects MHC class II genes against epigenetic silencing byDNAmethylation. J Immunol 183:2545-2553. http://dx.doi.org/10.4049/jimmunol.0900376.
62. Chang CH, Gourley TS, Sisk TJ. 2002. Function and regulation of class II transactivator in the immune system. Immunol Res 25:131-142. http://dx.doi.org/10.1385/IR:25:2:131.
63. Cressman DE, Chin KC, Taxman DJ, Ting JP. 1999. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity 10:163-171. http://dx.doi.org/10.1016/S1074-7613(00)80017-5.
64. Radosevich M, Song Z, Gorga JC, Ksander B, Ono SJ. 2004. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHCgenes in ocular melanoma cells. Invest Ophthalmol Vis Sci 45:3185-3195. http://dx.doi.org/10.1167/iovs.04-0111.
65. Garvie CW, Boss JM. 2008. Assembly of the RFX complex on the MHCII promoter: role of RFXAP and RFXB in relieving autoinhibition of RFX5. Biochim Biophys Acta 1779:797-804. http://dx.doi.org/10.1016/j.bbagrm.2008.07.012.
66. Schmid D, Pypaert M, Munz C. 2007. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 26:79-92. http://dx.doi.org/10.1016/j.immuni.2006.10.018.
67. Brown DM. 2010. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol 262:89-95. http://dx.doi.org/10.1016/j.cellimm.2010.02.008.
68. Glimcher LH, Kara CJ. 1992. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 10:13-49. http://dx.doi.org/10.1146/annurev.iy.10.040192.000305.
69. Long AB, Boss JM. 2005. Evolutionary conservation and characterization of the bare lymphocyte syndrome transcription factor RFX-B and its paralogue ANKRA2. Immunogenetics 56:788-797. http://dx.doi.org/10.1007/s00251-004-0738-2.
70. Barbera AJ, Chodaparambil JV, Kelley-Clarke B, Joukov V, Walter JC, Luger K, Kaye KM. 2006. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 311:856-861. http://dx.doi.org/10.1126/science.1120541.
71. Long AB, Ferguson AM, Majumder P, Nagarajan UM, Boss JM. 2006. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression. Mol Immunol 43:395-409. http://dx.doi.org/10.1016/j.molimm.2005.03.008.
72. Briggs L, Laird K, Boss JM, Garvie CW. 2009. Formation of the RFX gene regulatory complex induces folding of the interaction domain of RFXAP. Proteins 76:655-664. http://dx.doi.org/10.1002/prot.22379.
73. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP. 2000. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol 20:6051-6061. http://dx.doi.org/10.1128/MCB.20.16.6051-6061.2000.
74. Meissner TB, Liu YJ, Lee KH, Li A, Biswas A, van Eggermond MC, van den Elsen PJ, Kobayashi KS. 2012. NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression. J Immunol 188:4951-4958. http://dx.doi.org/10.4049/jimmunol.1103160.
75. Bihl F, Berger C, Chisholm JV, III, Henry LM, Bertisch B, Trojan A, Nadal D, Speck RF, Flepp M, Brander C, Mueller NJ, Swiss HIV Cohort Study. 2009. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. AIDS 23:1918-1922. http://dx.doi.org/10.1097/QAD.0b013e3283300a91.
76. Lepone L, Rappocciolo G, Knowlton E, Jais M, Piazza P, Jenkins FJ, Rinaldo CR. 2010. Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins. Clin Vaccine Immunol 17:1507-1516. http://dx.doi.org/10.1128/CVI.00189-10.
77. Duman S, Toz H, Asci G, Alper S, Ozkahya M, Unal I, Celik A, Ok E, Basci A. 2002. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 17:892-896. http://dx.doi.org/10.1093/ndt/17.5.892.
78. Kwun HJ, da Silva SR, Shah IM, Blake N, Moore PS, Chang Y. 2007. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J Virol 81:8225-8235. http://dx.doi.org/10.1128/JVI.00411-07.